{"denoms":[{"counts":[{"groupId":"BG000","value":"36"}],"units":"Participants"}],"groups":[{"description":"Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment","id":"BG000","title":"Bevacizumab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"20-29"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"30-39"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"40-49"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"50-59"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"60-69"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"70-79"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"80-89"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Eligibile and treatmed patients"}